// App-Quantinova.ai

TP1463 : Efficacy and safety outcomes for switching to lanadelumab from prior LTP: Findings from an interim analysis of the HELP OLE study

Researchers

Presenter

  • Magerl M

Principal Investigators

  • Kiani-Alikhan S

  • Riedl MA

  • Anderson JT

  • Nurse C

Medical Centers

  • Dept. of Dermatology and Allergy, Allergie-Centrum-Charite, Charite Universitatsmedizin Berlin, Germany, Berlin, Germany

  • Barts Health NHS Trust, London, United Kingdom

  • Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA

  • Clinical Research Center of Alabama, Birmingham Al, United States

  • Shire (now part of Takeda), Lexington Ma, United States

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • DX2930

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved